« Zurück
Home /
Daclatasvir (dihydrochloride)

Daclatasvir (dihydrochloride)

ArtNr	HY-10465-10mg
Hersteller	MedChem Express
CAS-Nr.	1009119-65-6
Menge	10 mg
Quantity options	100 mg 10mM/1mL 10 mg 50 mg 5 mg
Kategorie	Inhibitors & Compound Libraries Small Molecules
Typ	Inhibitors
Specific against	other
Purity	99.68
Formula	C40H52Cl2N8O6
Citations	EMBO Mol Med. 2024 Mar 10.<br/>Ann Hepatol. Nov-Dec 2019;18(6):816-824.<br/>Antimicrob Agents Chemother. 2013 Mar;57(3):1180-91.<br/>Antimicrob Agents Chemother. 2014 Aug;58(8):4555-64.<br/>Antimicrob Agents Chemother. 2014 Jun;58(6):3327-34. <br/>Antimicrob Agents Chemother. 2015 May;59(5):2496-507. <br/>Antivir Res. 2019 Nov;171:104612.<br/>Antiviral Res. 2017 Dec;148:5-14. <br/>Antiviral Res. 2017 Oct;146:191-200. <br/>Antiviral Res. 2020 May;177:104734.<br/>Biomed Pharmacother. 2019 May 16;116:108976.<br/>bioRxiv. 2020 May.<br/>Cell Rep. 2021 Nov 23;37(8):110049.<br/>College of Medicine/School of Medicine. Seoul National University. 2016 Aug.<br/>Department of Analytical Chemistry. Charles University. 2019 Jun.<br/>Drug Metab Dispos. 2019 Jul;47(7):768-778. <br/>EMBO Rep. 2016 Jul;17(7):1013-28.<br/>Eur J Med Chem. 2018 Jan 1;143:1053-1065.<br/>Eur J Pharmacol. 2019 Jun 15;853:111-120.<br/>Eur J Pharmacol. 2020 Sep 15;883:173323.<br/>Faculty of Pharmacy in Hradec Králové. Department of Pharmacology and Toxicology. Charles University 2019 Apr.<br/>Front Pharmacol. 2016 Dec 21;7:490. <br/>Front Pharmacol. 2018 Dec 19;9:1438.<br/>Hepatol Commun. 2017 Jul 13;1(6):550-563.<br/>Hepatology. 2019 May;69(5):1861-1872. <br/>Int J Antimicrob Agents. 2015 Oct;46(4):381-8. <br/>Int J Radiat Oncol Biol Phys. 2016 Nov 15;96(4):867-876. <br/>J Gastroenterol. 2019 May;54(5):449-458. <br/>J Hum Genet. 2020 Jan;65(2):143-153.<br/>J Med Chem. 2020 Jun 11;63(11):5972-5989.<br/>J Med Virol. 2023 Dec;95(12):e29290.<br/>J Virol. 2014 May;88(10):5578-94. <br/>Oncotarget. 2017 Dec 21;9(5):5627-5640.<br/>Open Virol J. 2014 Mar 7;8:1-8.<br/>Pharmaceuticals. 2022 Feb 18;15(2):242.<br/>PLoS One. 2015 Aug 11;10(8):e0134707. <br/>PLoS One. 2016 Apr 22;11(4):e0152036. <br/>PLoS One. 2016 Jul 21;11(7):e0159511.<br/>PLoS Pathog. 2017 May 11;13(5):e1006374. <br/>PLoS Pathog. 2018 Sep 18;14(9):e1007284. <br/>Sci Rep. 2018 Jun 6;8(1):8676. <br/>Transpl Infect Dis. 2018 Feb;20(1).<br/>Virus Res. 2017 May 2;235:37-48.<br/>Viruses. 2018 Aug 28;10(9). pii: E462.<br/>[1]Min Gao, et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010 May 6;465(7294):96-100.<br/>[2]David B Ascher, et al. Potent hepatitis C inhibitors bind directly to NS5A and reduce its affinity for RNA. Sci Rep. 2014 Apr 23;4:4765.<br/>[3]Tomomi Furihata, et al. Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides. Antimicrob Agents Chemother. 2014 Aug;58(8):4555-64.<br/>[4]Seung-Hoon Lee, et al. HA1077 displays synergistic activity with daclatasvir against hepatitis C virus and suppresses the emergence of NS5A resistance-associated substitutions in mice. Sci Rep. 2018 Aug 20;8(1):12469.
Smiles	O=C(N1CCC[C@H]1C2=NC=C(C3=CC=C(C4=CC=C(C=C4)C5=CN=C(N5)[C@@H]6CCCN6C([C@H](C(C)C)NC(OC)=O)=O)C=C3)N2)[C@H](C(C)C)NC(OC)=O.[H]Cl.[H]Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	BMS-790052 (dihydrochloride); EBP 883 (dihydrochloride)
Lieferbar
Product Description	Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir dihydrochloride is also an organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively[1][2][3].
StorageTemperature	4°C (Powder, sealed storage, away from moisture)
Shipping	Room Temperature
Manufacturers Applications	COVID-19-anti-virus
MolecularWeight	811.80
Clinical Information	Launched
Manufacturers Research Area	Infection
Solubility	DMSO : ≥ 56 mg/mL\|H2O : 50 mg/mL (ultrasonic)
Target	HCV
Manufacturers Target	HCV
Manufacturers Pathway	Anti-infection
Manufacturers Product type	Reference compound

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkdatenblatt anfordern

HY-10465-10mg-safety-datasheet.pdf